Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of Pfizer
Bio-Active Nanovesicles: Utilizing advanced plant-derived exosome technology to encapsulate and "shuttle" our Copper Tripeptide-1 (GHK-Cu) complex
Semaglutide, tirzepatide, and other pharmaceutical GLP-1 receptor agonists aren't listed on the supplied Supplement Facts panel, and this article didn't perform independent laboratory testing to confirm their absence beyond what the label discloses
Liraglutide (Victoza) followed in 2010, semaglutide (Ozempic) in 2017, oral semaglutide (Rybelsus) in 2019, semaglutide for weight loss (Wegovy) in 2021, and the first GIP/GLP-1 dual agonist tirzepatide (Mounjaro) in 2022 with its weight-loss sibling Zepbound in 2023
Development of biosimilars Biosimilars market is firmly established and constantly growing due to the emergence of new drugs and active ingredients like Liraglutide and Semaglutide
